NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• NUT midline carcinoma (NMC) is an aggressive squamous cell carcinoma.
• NMC often features BRD4/3-NUT fusion oncoproteins that inhibit cell differentiation and promote tumor growth.
• A subset of NMC cases involves NUT fused to uncharacterized genes.

Purpose of the Study:

• To establish and characterize a new patient-derived NMC cell line.
• To identify and investigate novel NUT fusion oncogenes in NMC.
• To explore the role of NSD3 in NMC pathogenesis and identify potential therapeutic targets.

Main Methods:

• Establishment of a patient-derived NMC cell line (1221).
• Characterization of the NSD3-NUT fusion oncogene in the 1221 cell line.
• Assessment of NSD3-NUT's necessity and sufficiency for differentiation blockade and proliferation.
• Investigation of NSD3-NUT binding to BRD4.
• Evaluation of BRD bromodomain inhibitors' effects on 1221 cells.
• Analysis of NSD3's role in BRD4-NUT-expressing NMCs.

Main Results:

• A novel NSD3-NUT fusion oncogene was identified in the 1221 NMC cell line.
• NSD3-NUT was found to be essential and sufficient for blocking differentiation and sustaining proliferation in NMC cells.
• NSD3-NUT binds to BRD4, and BRD bromodomain inhibitors induce differentiation and inhibit proliferation.
• NSD3 is crucial for differentiation blockade in NMC with BRD4-NUT fusions.

Conclusions:

• The identification of NSD3-NUT expands the known family of fusion oncogenes in squamous cell carcinoma.
• NSD3 acts as a critical oncogenic component in NMC, highlighting it as a potential therapeutic target.
• Aberrant differentiation mechanisms in NMC may offer insights into other squamous cell carcinomas.